Hlady Ryan A, Zhou Dan, Puszyk William, Roberts Lewis R, Liu Chen, Robertson Keith D
a Department of Molecular Pharmacology and Experimental Therapeutics , Mayo Clinic , Rochester , MN , USA.
b Shands Cancer Center, University of Florida , Gainesville , FL , USA.
Epigenetics. 2017 Mar 4;12(3):215-225. doi: 10.1080/15592294.2016.1277297. Epub 2017 Jan 6.
While intratumor heterogeneity contributes to disease progression, metastasis, and resistance to chemotherapy, it also provides a route to understanding the evolution and drivers of disease. Defects in epigenetic landscapes are intimately linked to pathogenesis of a variety of human diseases, with epigenetic deregulation promoting tumorigenesis. Understanding epigenetic heterogeneity is crucial in hepatocellular carcinoma (HCC), where epigenetic alterations are frequent, early, and pathogenic events. We determined genome-wide DNA methylation and copy number variation leveraging the Infinium 450K in a series of regenerative nodules from within single patient livers. Bioinformatics strategies were used to ascertain within-patient heterogeneity, link epigenetic changes to clinical features, and determine their relevance to disease pathogenesis. Our data demonstrate that DNA methylation and copy number alterations evolve during the pre-neoplastic phase of HCC and independently segregate regenerative nodules into distinct clusters. Regenerative nodules with a high frequency of epigenetic changes have significantly lower copy number variation, suggesting that individual nodules have differential enrichment of epigenetic and genetic components, with both contributing to disease progression. Regenerative nodules were scored based on 'epigenetic progression' with higher scores associated with increased proliferation measured by Ki67 staining. Early events observed in epigenetically 'aggressive' nodules are enriched for genes involved in liver cancer. Our study demonstrates that marked epigenetic and genetic heterogeneity exists in early pre-neoplastic liver tissue within individual patients, emphasizing the potential contributions of each mechanism to driving liver disease progression, and it unveils strategies for identifying epigenetic drivers of hepatocellular carcinoma.
虽然肿瘤内异质性会导致疾病进展、转移和化疗耐药,但它也为理解疾病的演变和驱动因素提供了一条途径。表观遗传景观的缺陷与多种人类疾病的发病机制密切相关,表观遗传失调促进肿瘤发生。在肝细胞癌(HCC)中,理解表观遗传异质性至关重要,因为表观遗传改变是频繁、早期且致病的事件。我们利用Infinium 450K技术测定了来自单个患者肝脏内一系列再生结节的全基因组DNA甲基化和拷贝数变异。采用生物信息学策略来确定患者内异质性,将表观遗传变化与临床特征联系起来,并确定它们与疾病发病机制的相关性。我们的数据表明,DNA甲基化和拷贝数改变在HCC的癌前阶段发生演变,并将再生结节独立地分为不同的簇。表观遗传变化频率高的再生结节拷贝数变异显著更低,这表明单个结节的表观遗传和遗传成分富集程度不同,两者都促成疾病进展。根据“表观遗传进展”对再生结节进行评分,得分越高与通过Ki67染色测量的增殖增加相关。在表观遗传上“侵袭性”结节中观察到的早期事件富含与肝癌相关的基因。我们的研究表明,单个患者的癌前肝组织中存在明显的表观遗传和遗传异质性,强调了每种机制对驱动肝病进展的潜在贡献,并揭示了识别肝细胞癌表观遗传驱动因素的策略。